Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz

HIV Medicine

Volumn 3, Issue 4, 2002, Pages 287-289

  Piketty, C ^a   Peytavin, G ^b   Trylezinski, A ^a   Gonzalez Canali, G ^a   Castiel, P ^a   Weiss, L ^a   Kazatchkine, M D ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Efavirenz; HIV infection; Lipid abnormalities; Ritonavir; Saquinavir

Indexed keywords

CHOLESTEROL; EFAVIRENZ; GLUCOSE; INDINAVIR; LIPID; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INSOMNIA; LIPID BLOOD LEVEL; PRIORITY JOURNAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO;

BLOOD GLUCOSE; CHOLESTEROL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; TRIGLYCERIDES;

EID: 18744386081     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2002.00126.x     Document Type: Article

References (8)

1. Piketty C, Race E, Castiel P et al. Phenotypic resistance to protease inhibitors in patients who fail on HAART predicts the outcome at 48 weeks of a five drug combination including ritonavir, saquinavir and efavirenz. AIDS 2000; 14: 626-628.
2. Piketty C, Race E, Castiel P et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999; 13: F71-F77.
3. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
4. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy. Arch Intern Med 2000; 160: 2050-2056.
5. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100: 700-705.
6. Danner SA, Carr A, Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-1533.
7. Hsu A, Granneman GR, Witt G et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997; 41: 898-905.
8. Doser N, Sudre P, Telenti A et al. Persistent dyslipidemia in HIV-infected individuals switched from protease inhibitor-containing to an efavirenz-containing regimen. J Acquir Immune Defic Syndr 2001; 26: 389-390.